A5051936901- Glioma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Breast Cancer Treatment Studies
- Neuroblastoma Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Histone Deacetylase Inhibitors Research
- Cancer Treatment and Pharmacology
- Circular RNAs in diseases
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Vascular Tumors and Angiosarcomas
- Ocular Oncology and Treatments
- Chromatin Remodeling and Cancer
- Colorectal and Anal Carcinomas
- Cardiac tumors and thrombi
- Hedgehog Signaling Pathway Studies
- Medical Imaging Techniques and Applications
- Estrogen and related hormone effects
- Optimism, Hope, and Well-being
- Chemotherapy-induced cardiotoxicity and mitigation
- Epigenetics and DNA Methylation
Azienda USL di Bologna
2018-2024
Medica (Italy)
2017-2023
Aurelia Hospital
2023
Ospedale Bellaria
2023
Institute of Neurological Sciences
2017-2020
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2020
Policlinico S.Orsola-Malpighi
2012-2017
University of Bologna
2015-2017
Fondazione IRCCS Istituto Nazionale dei Tumori
2017
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We present final analysis of phase III noninferiority, randomized ShortHER comparing 9 weeks versus 1 year adjuvant...
Abstract Background Medulloblastoma is extremely rare in adults. The role of chemotherapy for average-risk adult patients remains controversial. Surgery and radiotherapy provide a significant disease control good prognosis, but about 25% have relapse die because progression. No data are available to compareradiotherapy alone radiotherapyfollowed byadjuvant chemotherapy. Methods We analyzed 48 according Chang classification diagnosed from 1988 2016. Results Median age was 29 years (range...
Aim: To evaluate relevance of clinical and molecular factors in adult low-grade gliomas (LGG) to correlate with survival. Methods: We reviewed records from LGG patients 1991 2015 who received surgery had sufficient tissue biomarkers characterization. Results: 213 consecutive were included: 17.4% low-risk, according Radiation Therapy Oncology Group (RTOG) risk assessment. IDH 1/2 mutation, 1p/19q co-deletion, MGMT methylation found 93, 50.8 65.3% patients. Median follow-up was 98.3 months. In...
LBA637 Background: The ShortHER trial is a phase III non-inferiority, randomized comparing 9 weeks (short arm) versus 1 year (long of adjuvant trastuzumab combined with chemotherapy in HER2+ eBC patients. first primary end point the study was event-driven analysis disease-free survival which achieved 2017, presented at ASCO 2017 and published Annals Oncology 2018. HR 1.13 (90% CI 0.89-1.42) non-inferiority could not be claimed as upper border crossed limit 1.29 chosen margin. According to...
Aim: To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression. Methods: We retrospectively evaluated 106 had nonprogressive first magnetic resonance imaging completion radiotherapy, a treatment-free interval (TFI) least 8 weeks received or nitrosourea Results: In TFI ≥5 months, median survival was 17.7 11.6 months progression-free 8.1 5.8 in group, respectively....
Primary cardiac angiosarcoma is extremely aggressive; however, it often misdiagnosed because of its rarity. For locally advanced tumors, doxorubicin-based chemotherapy regimens are the standard treatment, even if gain in term progression-free survival limited and no longer than 5 months. We report case a Caucasian 23-year-old man with who underwent radical surgical resection after prolonged response to weekly docetaxel complementary radiotherapy. Combined treatment radiotherapy may be valid...
Abstract Background The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown increase the pathological complete response (pCR) rate, without main safety concerns. aim NeoPowER trial is evaluate efficacy P H CT in a real–world population. Methods We retrospectively reviewed medical records stage II–III, BC treated NaT: who received (neopower group) 5 Emilia Romagna institutions were...
2017 Background: Molecular characterization of low grade gliomas (LGG) is essential for diagnosis and treatment these diseases. LGG patients (pts) with IDH mutation 1p19q codeletion (codel) are characterized by a median OS (mOS) longer than 10 years. Thus, the role treatments side effects should be carefully evaluated. Methods: We evaluated pts from our data warehouse (n=679 pts) who received surgery had sufficient tissue to assess biomarkers characterization. Pts gliomatosis were excluded....
Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially anthracyclines. Cardiac function damage is generally rare, precox and mild alone. We report the case of a 49 year-old woman affected by metastatic breast cancer who developed trastuzumab-related cardiogenic shock due to pump failure (with LVEF about 15%) after three months treatment. After long hospitalization cardiac intensive care unit proper treatment,...
Patients with low-grade gliomas (LGGs) isocitrate dehydrogenase (IDH) mutation (mut) and 1p19q codeletion (codel) have a median overall survival of longer than 10 years. The aim this study is to assess the role postsurgical treatments.We evaluated patients LGGs IDH mut codel; IDH1/2 was performed by immunohistochemistry quantitative polymerase chain reaction. In all wild-type cases, we next-generation sequencing. 1p19 codel analysis fluorescence in situ hybridization.Among 679 patients, 93...
Medulloblastoma is a rare tumor in adults and the use of adjuvant chemotherapy average risk patients debated.Patients included our study were ⩾16 years age, had histologically confirmed medulloblastoma, underwent radiotherapy with or without chemotherapy. Average was defined according to Chang classification.We 48 average-risk patients. Median follow-up 151.5 months (95% confidence interval, 124.5-178.5). Both progression-free survival (PFS) overall (OS) significantly influenced by (PFS:...
e13057 Background: Metabolic clearance of fluoropyrimidines is highly dependent on the rate-limiting enzyme dihydropyrimidine dehydrogenase (DPD). Deficiency DPD associated with drug accumulation and severe toxicities. The gene (DPYD) polymorphic; however, except G>A mutation in splicing consensus sequence intron 14 (IVS14+1G>A), which responsible impairment, association other variants adverse reactions unclear. Therefore, this study was aimed at examining prevalence DPYD patients...
2037 Background: Medulloblastoma is extremely rare in adults and, therefore, it difficult to accrual patients clinical trials. Radical surgery and radiotherapy (RT) provide a significant control of disease. Nevertheless, about 25% average-risk have relapse die because disease progression. The role chemotherapy (CT) after standard RT for adult remains controversial. Methods: We analyzed 48 according Chang classification diagnosed from 1988 2016. Median age was 29 years (range 16-61), M/F...
Abstract Background: Current guidelines for BC surveillance in asymptomatic pts recommend annual mammography and periodical physical examination. These recommendations arise from two trials conducted the 1980's: since then no other randomized controlled (RCTs) have been on follow-up. However our knowledge biology, diagnosis of metastases treatment has improved. The aim this prospective RCT is to verify if serial measurement CEA CA15.3 (followed by 18-FDG PET) can anticipate breast cancer...